Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2024

Open Access 01-12-2024 | Urinary Tract Infection | Research

Phage vB_Ec_ZCEC14 to treat antibiotic-resistant Escherichia coli isolated from urinary tract infections

Authors: Nedaa M. Ismael, Mohamed Azzam, Mohamed Abdelmoteleb, Ayman El-Shibiny

Published in: Virology Journal | Issue 1/2024

Login to get access

Abstract

Escherichia coli is a commensal bacterial species in the human gastrointestinal tract; however, it could be pathogenic and cause severe infections in intra and extra-intestinal sites. Uropathogenic E. coli accounts for 80–90% of urinary tract infections that can result in urosepsis and septic shock. Consequently, multidrug-resistant uropathogenic E. coli poses a considerable risk to the healthcare system worldwide. Phage therapy is demonstrated as an optimistic solution to over-the-counter antibiotics that contribute to the global issue of multidrug-resistant bacteria. This study aims to isolate a novel phage that could be implemented to cure urinary tract infections mediated by multidrug-resistant E. coli. Twenty-seven E. coli isolates were collected from patients with urinary tract infections to assess the antibacterial efficacy of phage vB_Ec_ZCEC14. Phage kinetics were encountered against the E. coli strain (EC/4), in addition to evaluating phage stability under various temperatures, pH values, and UV exposure periods. Full genome sequencing and morphological analysis were conducted for further phage characterization, which revealed that phage vB_Ec_ZCEC14 belongs to the family Straboviridae. Phage vB_Ec_ZCEC14 showed thermal tolerance at 80 ℃, pH stability between pH 3 and pH 12, and endurance to UV exposure for 45 min. The phage-host interaction results revealed that phage vB_Ec_ZCEC14 has strong and steady antibacterial action at lower concentrations (MOI 0.1). The study findings strongly indicate that phage vB_Ec_ZCEC14 holds significant promise as a potential therapeutic alternative for treatment of antibiotic-resistant uropathogenic E. coli.
Appendix
Available only for authorised users
Literature
1.
Al-Anany AM, Hooey PB, Cook JD, Burrows LL, Martyniuk J, Hynes AP, et al. Phage therapy in the management of urinary tract infections: a comprehensive systematic review. PHAGE. 2023;4:112–27.PubMedPubMedCentralCrossRef
2.
Zalewska-Piątek B, Piątek R. Phage therapy as a novel strategy in the treatment of urinary tract infections caused by E. Coli. Antibiotics. 2020;9:304.PubMedPubMedCentralCrossRef
3.
Lin W-H, Wang M-C, Liu P-Y, Chen P-S, Wen L-L, Teng C-H, et al. Escherichia coli urinary tract infections: host age-related differences in bacterial virulence factors and antimicrobial susceptibility. J Microbiol Immunol Infect. 2022;55:249–56.PubMedCrossRef
4.
Critchley IA, Cotroneo N, Pucci MJ, Mendes R. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS ONE. 2019;14:e0220265.PubMedPubMedCentralCrossRef
5.
Paul R, Srivastava S, Muhammad T, Rashmi R. Determinants of acquired disability and recovery from disability in Indian older adults: longitudinal influence of socio-economic and health-related factors. BMC Geriatr. 2021;21:426.PubMedPubMedCentralCrossRef
6.
7.
8.
9.
Nascimento JAS, Santos FF, Valiatti TB, Santos-Neto JF, Santos ACM, Cayô R et al. Frequency and diversity of hybrid escherichia coli strains isolated from urinary tract infections. Microorganisms. 2021;9.
10.
11.
Katouli M. Population structure of gut Escherichia coli and its role in development of extra-intestinal infections. Iran J Microbiol. 2010;2:59.PubMedPubMedCentral
12.
Alanazi MQ, Alqahtani FY, Aleanizy FS. An evaluation of E. Coli in urinary tract infection in emergency department at KAMC in Riyadh, Saudi Arabia: retrospective study. Ann Clin Microbiol Antimicrob. 2018;17:3.PubMedPubMedCentralCrossRef
13.
Amadu DO, Nwabuisi C, Yunusa T, Nasir IA, Oladejo JM, Seibu E, et al. Prevalence and associated factors associated with uropathogenic Escherichia coli isolates from catheterized persons at Ilorin Tertiary Hospital, Nigeria. Afro-Egyptian J Infect Endemic Dis. 2019;9:119–28.CrossRef
14.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Reviews Microbiol 2015. 2015;13:5.
15.
Allocati N, Masulli M, Alexeyev MF, Ilio C, Di. Escherichia coli in Europe: an overview. OPEN ACCESS Int J Environ Res Public Health. 2013;10:10.
16.
Talebi Bezmin Abadi A, Rizvanov AA, Haertlé T, Blatt NL. World Health Organization report: current crisis of antibiotic resistance. BioNanoScience. 2019;9:778–88.CrossRef
17.
Ramadan H, Soliman AM, Hiott LM, Elbediwi M, Woodley TA, Chattaway MA, et al. Emergence of multidrug-resistant Escherichia coli producing CTX-M, MCR-1, and FosA in retail food from Egypt. Front Cell Infect Microbiol. 2021;11:559.CrossRef
18.
Mattila S, Ruotsalainen P, Jalasvuori M. On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front Microbiol. 2015;6:1271.PubMedPubMedCentralCrossRef
19.
20.
Luong T, Salabarria AC, Roach DR. Phage therapy in the resistance era: where do we stand and where are we going? Clin Ther. 2020;42:1659–80.PubMedCrossRef
21.
Golkar Z, Bagasra O, Gene Pace D. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J Infect Developing Ctries. 2014;8:129–36.CrossRef
22.
23.
Slopek S, Durlakowa I, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Arch Immunol Ther Exp (Warsz). 1984;32:317–35.PubMed
24.
Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. V. evaluation of the results obtained in children. Arch Immunol Ther Exp (Warsz). 1985;33:241–59.PubMed
25.
Silva C, Sá S, Guedes C, Oliveira C, Lima C, Oliveira M, et al. The history and applications of phage therapy in pseudomonas aeruginosa. Microbiol Res. 2022;13:14–37.CrossRef
26.
Neamati F, Firoozeh F, Saffari M, Zibaei M. Virulence genes and antimicrobial resistance pattern in uropathogenic Escherichia coli isolated from hospitalized patients in Kashan, Iran. Jundishapur J Microbiol. 2015;8:e17514.PubMedPubMedCentralCrossRef
27.
Takahashi A, Kanamaru S, Kurazono H, Kunishima Y, Tsukamoto T, Ogawa O, et al. Escherichia coli isolates associated with uncomplicated and complicated cystitis and asymptomatic bacteriuria possess similar phylogenies, virulence genes, and O-serogroup profiles. J Clin Microbiol. 2006;44:4589–92.PubMedPubMedCentralCrossRef
28.
Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M. Spread of extended-spectrum β-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrob Agents Chemother. 2007;51:1946–55.PubMedPubMedCentralCrossRef
29.
Adesiji YO, Shivakumaraswamy SK, Kumar Deekshit V, Kallappa GS, Karunasagar I, Adesiji Y. Molecular characterization of antimicrobial multi-drug resistance in non-typhoidal salmonellae from chicken and clam in Mangalore, India. J Biomedical Res. 2018;32:237–44.CrossRef
30.
Kpoda DS, Ajayi A, Somda M, Traore O, Guessennd N, Ouattara AS, et al. Distribution of resistance genes encoding ESBLs in enterobacteriaceae isolated from biological samples in health centers in Ouagadougou, Burkina Faso. BMC Res Notes. 2018;11:471.PubMedPubMedCentralCrossRef
31.
Sid Ahmed MA, Bansal D, Acharya A, Elmi AA, Hamid JM, Sid Ahmed AM, et al. Antimicrobial susceptibility and molecular epidemiology of extended-spectrum beta-lactamase-producing enterobacteriaceae from intensive care units at Hamad medical corporation, Qatar. Antimicrob Resist Infect Control. 2016;5:1–6.CrossRef
32.
KIRBY WM, YOSHIHARA GM, WARREN SUNDSTEDKS. JH. Clinical usefulness of a single disc method for antibiotic sensitivity testing. Antibiot Annual. 1956;892–7.
33.
Daoud N, Hamdoun M, Hannachi H, Gharsallah C, Mallekh W, Bahri O. Antimicrobial susceptibility patterns of Escherichia coli among Tunisian outpatients with community-acquired urinary tract infection (2012–2018). Curr Urol. 2020;14:200–5.PubMedPubMedCentralCrossRef
34.
Kidsley AK, Abraham S, Bell JM, O’Dea M, Laird TJ, Jordan D, et al. Antimicrobial susceptibility of Escherichia coli and Salmonella Spp. Isolates from healthy pigs in Australia: results of a Pilot National Survey. Front Microbiol. 2018;9:1207.PubMedPubMedCentralCrossRef
35.
36.
Makky S, Abdelsattar AS, Habashy M, Dawoud A, Nofal R, Hassan A, et al. Phage ZCSS1 from isolation to application against Staphylococcus sciuri and biofilm: a prospect of utilizing temperate phage and its products. Gene Rep. 2023;32:101792.CrossRef
37.
Bourdin G, Schmitt B, Guy LM, Germond JE, Zuber S, Michot L, et al. Amplification and purification of T4-like Escherichia coli phages for phage therapy: from laboratory to pilot scale. Appl Environ Microbiol. 2014;80:1469–76.PubMedPubMedCentralCrossRefADS
38.
Maaløe O, Watson JD. The transfer of radioactive phosphorus from parental to progeny phage. P Natl A Sci. 1951;37:507–13.
39.
Echeverría-Vega A, Morales-Vicencio P, Saez-Saavedra C, Gordillo-Fuenzalida F, Araya R. A rapid and simple protocol for the isolation of bacteriophages from coastal organisms. MethodsX. 2019;6:2614–9.PubMedPubMedCentralCrossRef
40.
Schiettekatte O, Bourhy P. Isolation, purification, and characterization of leptophages. Methods Mol Biol. 2020;2134:67–75.PubMedCrossRef
41.
Makky S, Rezk N, Abdelsattar AS, Hussein AH, Eid A, Essam K, et al. Characterization of the biosynthesized syzygium aromaticum-mediated silver nanoparticles and its antibacterial and antibiofilm activity in combination with bacteriophage. Results in Chemistry. 2023;5:100686.CrossRef
42.
Fayez MS, Hakim TA, Zaki BM, Makky S, Abdelmoteleb M, Essam K, et al. Morphological, biological, and genomic characterization of Klebsiella pneumoniae phage vB_Kpn_ZC2. Virol J. 2023;20:86.PubMedPubMedCentralCrossRef
43.
Islam MS, Zhou Y, Liang L, Nime I, Liu K, Yan T, et al. Application of a phage cocktail for control of salmonella in foods and reducing biofilms. Viruses. 2019;11:841.PubMedPubMedCentralCrossRef
44.
Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of bacteriophages using the small drop plaque assay system. Methods in molecular biology (Clifton NJ). 2009;501:81–5.
45.
Anand T, Virmani N, Kumar S, Mohanty AK, Pavulraj S, Bera BC, et al. Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J Global Antimicrob Resist. 2020;21:34–41.CrossRef
46.
El-Tawab A, Isolation. Characterization, and efficacy of three lytic phages infecting multidrug-resistant salmonella serovars from poultry farms in Egypt. Arch Razi Inst. 2021;76:507–19.
47.
O’Flynn G, Ross RP, Fitzgerald GF, Coffey A. Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl Environ Microbiol. 2004;70:3417–24.PubMedPubMedCentralCrossRefADS
48.
Kutter E. Phage host range and efficiency of plating. Methods in molecular biology. (Clifton NJ). 2009;501:141–9.
49.
Cerveny KE, DePaola A, Duckworth DH, Gulig PA. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun. 2002;70:6251–62.PubMedPubMedCentralCrossRef
50.
Fayez MS, Hakim TA, Agwa MM, Abdelmoteleb M, Aly RG, Montaser NN et al. Topically applied bacteriophage to control multi-drug resistant klebsiella pneumoniae infected wound in a rat model. Antibiotics. 2021;10.
51.
Louie M, Jayaratne P, Luchsinger I, Devenish J, Yao J, Schlech W, et al. Comparison of ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for molecular typing of Listeria monocytogenes. J Clin Microbiol. 1996;34:15–9.PubMedPubMedCentralCrossRef
52.
Esmael A, Azab E, Gobouri AA, Nasr-Eldin MA, Moustafa MMA, Mohamed SA, et al. Isolation and characterization of two lytic bacteriophages infecting a multi-drug resistant salmonella typhimurium and their efficacy to combat salmonellosis in ready-to-use foods. Microorganisms. 2021;9:423.PubMedPubMedCentralCrossRef
53.
Armon R, Kott Y. A simple, rapid and sensitive presence/absence detection test for bacteriophage in drinking water. J Appl Bacteriol. 1993;74:490–6.PubMedCrossRef
54.
Miles AA, Misra SS, Irwin JO. The estimation of the bactericidal power of the blood. J Hygiene. 1938;38:732–49.
55.
Zaki BM, Fahmy NA, Aziz RK, Samir R, El-Shibiny A. Characterization and comprehensive genome analysis of novel bacteriophage, vB_Kpn_ZCKp20p, with lytic and anti-biofilm potential against clinical multidrug-resistant Klebsiella pneumoniae. Front Cell Infect Microbiol. 2023;13:3.CrossRef
56.
Valério N, Oliveira C, Jesus V, Branco T, Pereira C, Moreirinha C, et al. Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli. Virus Res. 2017;240:8–17.PubMedCrossRef
57.
Clarke AL, De Soir S, Jones JD. The safety and efficacy of phage therapy for bone and joint infections: a systematic review. Antibiot (Basel Switzerland). 2020;9:1–11.
58.
59.
60.
Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biology: J Comput Mol cell Biology. 2012;19:455–77.MathSciNetCrossRef
61.
Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinf (Oxford England). 2013;29:1072–5.
62.
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403–10.PubMedCrossRef
63.
Davis JJ, Wattam AR, Aziz RK, Brettin T, Butler R, Butler RM, et al. The PATRIC bioinformatics resource center: expanding data and analysis capabilities. Nucleic Acids Res. 2020;48:D606–12.PubMed
64.
Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, et al. The RAST server: rapid annotations using subsystems technology. BMC Genomics. 2008;9:75.PubMedPubMedCentralCrossRef
65.
Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–80.PubMedPubMedCentralCrossRef
66.
67.
68.
Meier-Kolthoff JP, Auch AF, Klenk H-P, Göker M. Genome sequence-based species delimitation with confidence intervals and improved distance functions. BMC Bioinformatics. 2013;14:60.PubMedPubMedCentralCrossRef
69.
Moraru C, Varsani A, Kropinski AM. VIRIDIC-A novel tool to calculate the intergenomic similarities of prokaryote-infecting viruses. Viruses. 2020;12:1268.PubMedPubMedCentralCrossRef
70.
Nishimura Y, Yoshida T, Kuronishi M, Uehara H, Ogata H, Goto S. ViPTree: the viral proteomic tree server. Bioinf (Oxford England). 2017;33:2379–80.
71.
Turner D, Reynolds D, Seto D, Mahadevan P. CoreGenes3.5: a webserver for the determination of core genes from sets of viral and small bacterial genomes. BMC Res Notes. 2013;6:140.PubMedPubMedCentralCrossRef
72.
73.
74.
75.
Abdelrahman F, Rezk N, Fayez MS, Abdelmoteleb M, Atteya R, Elhadidy M, et al. Isolation, characterization, and genomic analysis of three novel E. Coli bacteriophages that effectively infect E. Coli O18. Microorganisms. 2022;10:589.PubMedPubMedCentralCrossRef
76.
77.
Chapman TA, Wu XY, Barchia I, Bettelheim KA, Driesen S, Trott D, et al. Comparison of virulence gene profiles of Escherichia coli strains isolated from healthy and diarrheic swine. Appl Environ Microbiol. 2006;72:4782.PubMedPubMedCentralCrossRefADS
78.
Malekzadegan Y, Khashei R, Sedigh Ebrahim-Saraie H, Jahanabadi Z. Distribution of virulence genes and their association with antimicrobial resistance among uropathogenic Escherichia coli isolates from Iranian patients 11 medical and health sciences 1108 medical microbiology. BMC Infect Dis. 2018;18.
79.
Rezatofighi SE, Mirzarazi M, Salehi M. Virulence genes and phylogenetic groups of uropathogenic Escherichia coli isolates from patients with urinary tract infection and uninfected control subjects: a case-control study. BMC Infect Dis. 2021;21:1–11.CrossRef
80.
Abd El-Baky RM, Ibrahim RA, Mohamed DS, Ahmed EF, Hashem ZS. Prevalence of virulence genes and their association with antimicrobial resistance among pathogenic E. Coli isolated from Egyptian patients with different clinical infections. Infect Drug Resist. 2020;13:1221–36.PubMedPubMedCentralCrossRef
81.
Firoozeh F, Saffari M, Neamati F, Zibaei M. Detection of virulence genes in Escherichia coli isolated from patients with cystitis and pyelonephritis. Int J Infect Dis. 2014;29:219–22.PubMedCrossRef
82.
El-baz R, Said HS, Abdelmegeed ES, Barwa R. Characterization of virulence determinants and phylogenetic background of multiple and extensively drug resistant Escherichia coli isolated from different clinical sources in Egypt. Appl Microbiol Biotechnol. 2022;106:1279–98.PubMedPubMedCentralCrossRef
83.
Bryskier A. Penicillins Antimicrob Agents. 2014;113–62.
84.
Islam MS, Sobur MA, Rahman S, Ballah FM, Ievy S, Siddique MP, et al. Detection of blaTEM, blaCTX-M, blaCMY, and blaSHV genes among extended-spectrum beta-lactamase-producing Escherichia coli isolated from migratory birds travelling to Bangladesh. Microb Ecol. 2021;83:942–50.PubMedPubMedCentralCrossRefADS
85.
Ngaiganam EP, Pagnier I, Chaalal W, Leangapichart T, Chabou S, Rolain JM, et al. Investigation of urban birds as source of β-lactamase-producing Gram-negative bacteria in Marseille city, France. Acta Vet Scand. 2019;61:1–7.CrossRef
86.
D’Andrea MM, Arena F, Pallecchi L, Rossolini GM. CTX-M-type β-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol. 2013;303:305–17.PubMedCrossRef
87.
Seyedjavadi SS, Goudarzi M, Sabzehali F. Relation between blaTEM, blaSHV and blaCTX-M genes and acute urinary tract infections. J Acute Disease. 2016;5:71–6.CrossRef
88.
Barlow M, Reik RA, Jacobs SD, Medina M, Meyer MP, McGowan JE, et al. High rate of mobilization for blaCTX-Ms - volume 14, number 3—March 2008 - emerging infectious diseases journal - CDC. Emerg Infect Dis. 2008;14:423–8.PubMedPubMedCentralCrossRef
89.
Hamed H, Gaber A, EL Sehsah EM, Author C, Hamed Saleh H. Detection of β-lactamase genes (blaTEM, Bla CTX-M and bla SHV) in uropathogens isolated from patients with UTI Key words: Beta-lactamase genes{bla(TEM), bla(CTX-M), and Bla(SHV)}, uropathogens, and UTI. Egypt J Med Microbiol. 2021;30:97–103.CrossRef
90.
91.
Levy SB, McMurry LM, Burdett V, Courvalin P, Hillen W, Roberts MC, et al. Nomenclature for tetracycline resistance determinants. Antimicrob Agents Chemother. 1989;33:1373–4.PubMedPubMedCentralCrossRef
92.
Levy SB, McMurry LM, Barbosa TM, Burdett V, Courvalin P, Hillen W, et al. Nomenclature for new tetracycline resistance determinants. Antimicrob Agents Chemother. 1999;43:1523–4.PubMedPubMedCentralCrossRef
93.
Guillaume G, Verbrugge D, Chasseur-Libotte ML, Moens W, Collard JM. PCR typing of tetracycline resistance determinants (Tet A–E) in Salmonella enterica serotype Hadar and in the microbial community of activated sludges from hospital and urban wastewater treatment facilities in Belgium. FEMS Microbiol Ecol. 2000;32:77–85.PubMed
Metadata
Title
Phage vB_Ec_ZCEC14 to treat antibiotic-resistant Escherichia coli isolated from urinary tract infections
Authors
Nedaa M. Ismael
Mohamed Azzam
Mohamed Abdelmoteleb
Ayman El-Shibiny
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2024
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-024-02306-0

Other articles of this Issue 1/2024

Virology Journal 1/2024 Go to the issue

Research

Prevalence of high and low risk HPV genotypes among vaccinated and non-vaccinated people in Tehran

Research

Does COVID-19 affect sperm quality in males? the answer may be yes, but only temporarily

Review

SARS-CoV-2 outbreak: role of viral proteins and genomic diversity in virus infection and COVID-19 progression

Research

Quercetin inhibits SARS-CoV-2 infection and prevents syncytium formation by cells co-expressing the viral spike protein and human ACE2

Research

Bacterial isolation and genome analysis of a novel Klebsiella quasipneumoniae phage in southwest China’s karst area

Review

Exosome-mediated regulation of inflammatory pathway during respiratory viral disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits